Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has appointed Brian Adams as Chief Legal Officer and Corporate Secretary. Adams brings nearly two decades of life sciences leadership experience and will oversee the company's legal, governance, and intellectual property functions.
Adams joins from Relay Therapeutics where he served as Chief Legal Officer. His previous experience includes senior roles at Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology, and Genzyme Corporation. He succeeds Ellen Chiniara, who is retiring to focus on board service and advisory opportunities.
Kymera Therapeutics (NASDAQ: KYMR), azienda biofarmaceutica in fase clinica specializzata nello sviluppo di farmaci degradanti per via orale a piccola molecola, ha nominato Brian Adams Chief Legal Officer e Corporate Secretary. Adams porta con sé quasi venti anni di esperienza dirigenziale nel settore delle scienze della vita e sarà responsabile delle funzioni legali, di governance e della proprietà intellettuale della società.
Adams arriva da Relay Therapeutics, dove ricopriva il ruolo di Chief Legal Officer. In precedenza ha ricoperto posizioni di rilievo presso Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology e Genzyme Corporation. Sostituisce Ellen Chiniara, che si ritira per concentrarsi su incarichi nel consiglio di amministrazione e attività di consulenza.
Kymera Therapeutics (NASDAQ: KYMR), una compañía biofarmacéutica en fase clínica centrada en desarrollar medicamentos degradadores orales de pequeña molécula, ha nombrado a Brian Adams como Chief Legal Officer y Corporate Secretary. Adams aporta casi dos décadas de experiencia en puestos de liderazgo en ciencias de la vida y supervisará las funciones legales, de gobernanza y de propiedad intelectual de la empresa.
Adams procede de Relay Therapeutics, donde se desempeñó como Chief Legal Officer. Anteriormente ocupó cargos directivos en Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology y Genzyme Corporation. Sustituye a Ellen Chiniara, que se retira para centrarse en su labor en juntas directivas y en actividades de asesoramiento.
Kymera Therapeutics (NASDAQ: KYMR), 경구용 소분자 분해제 의약품 개발에 주력하는 임상 단계 생명공학 기업이 Brian Adams를 Chief Legal Officer 및 Corporate Secretary로 임명했습니다. Adams는 거의 20년에 달하는 생명과학 분야의 리더십 경험을 보유하고 있으며 회사의 법무, 거버넌스 및 지식재산권 업무를 총괄하게 됩니다.
Adams는 Relay Therapeutics에서 Chief Legal Officer로 재직한 경력이 있습니다. 이전에는 Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology 및 Genzyme Corporation 등에서 고위직을 역임했습니다. 그는 이사직 및 자문 활동에 전념하기 위해 은퇴하는 Ellen Chiniara의 뒤를 잇습니다.
Kymera Therapeutics (NASDAQ: KYMR), une société biopharmaceutique en phase clinique axée sur le développement de médicaments dégradeurs oraux de petites molécules, a nommé Brian Adams au poste de Chief Legal Officer et Corporate Secretary. Adams apporte près de vingt ans d'expérience de direction dans les sciences de la vie et supervisera les fonctions juridiques, de gouvernance et de propriété intellectuelle de l'entreprise.
Adams rejoint Kymera depuis Relay Therapeutics, où il était Chief Legal Officer. Il a auparavant occupé des postes de haut niveau chez Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology et Genzyme Corporation. Il succède à Ellen Chiniara, qui prend sa retraite pour se consacrer à des missions de conseil et à des fonctions au sein de conseils d'administration.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung oraler, kleinmolekularer Degrader-Medikamente konzentriert, hat Brian Adams zum Chief Legal Officer und Corporate Secretary ernannt. Adams bringt fast zwei Jahrzehnte Führungserfahrung im Bereich Life Sciences mit und wird die Rechts-, Governance- und geistigen Eigentumsangelegenheiten des Unternehmens leiten.
Adams kommt von Relay Therapeutics, wo er als Chief Legal Officer tätig war. Zuvor hatte er leitende Positionen bei Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology und Genzyme Corporation inne. Er tritt die Nachfolge von Ellen Chiniara an, die in den Ruhestand geht, um sich auf Vorstandstätigkeiten und Beratungsaufgaben zu konzentrieren.
- Appointment of experienced legal executive with nearly 20 years of life sciences leadership
- Strategic addition to support clinical development and commercialization plans
- None.
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera’s legal, governance, and intellectual property functions. Mr. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and other advisory opportunities.
“Kymera is building a fully integrated global medicines company focused on transforming care for millions of patients living with immuno-inflammatory diseases through our portfolio of first-in-class oral medicines with biologics-like profiles,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “We’re thrilled to welcome Brian to our team. His proven leadership and deep expertise will be instrumental as we advance and scale our novel programs through clinical development and toward commercialization. Additionally, we would like to sincerely thank Ellen for her strong dedication and many contributions to Kymera’s success throughout the company’s remarkable growth and wish her the best as she pursues her next chapter.”
“I was drawn to Kymera by its unwavering commitment to long-term scientific innovation and meaningful clinical impact,” said Mr. Adams. “I am thrilled to be joining the company at such an exciting time of progress and look forward to working with this pioneering team as we strive to redefine what’s possible in immunology with groundbreaking oral medicines.”
Before joining Kymera, Mr. Adams was Chief Legal Officer of Relay Therapeutics, responsible for leading all aspects of Relay’s legal and compliance operations. Prior to Relay, he served as Senior Vice President, General Counsel and Secretary at Keryx Biopharmaceuticals. Earlier in his career, he held senior roles at Algeta ASA, AVEO Oncology, and Genzyme Corporation. Additionally, he practiced at Bingham McCutchen LLP, where he advised private equity sponsors, biotechs, and other emerging technology companies on a broad range of corporate matters and financing transactions. Mr. Adams holds a B.A. from Harvard University and a J.D. from the Catholic University of America’s Columbus School of Law.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Availability of Other Information About Kymera Therapeutics
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
Who is the new Chief Legal Officer of Kymera Therapeutics (NASDAQ: KYMR)?
What is Brian Adams' experience before joining Kymera Therapeutics?
Who did Brian Adams replace as Chief Legal Officer at Kymera?
What will be Brian Adams' responsibilities at Kymera Therapeutics?
